This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.
Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?
by Zacks Equity Research
Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.
Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.
Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
by Zacks Equity Research
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.
Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.
DaVita (DVA) Announces Preliminary Q2 Results, View Upbeat
by Zacks Equity Research
Management at DaVita (DVA) expects impressive contribution from calcimimetics in Q2.
What's in Store for Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?
by Zacks Equity Research
NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.
Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.
Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.
Analytical Instruments to Aid Thermo Fisher (TMO) Q2 Earnings?
by Zacks Equity Research
Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.
What's in the Offing for Cerner's (CERN) Earnings in Q2?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.
What's in Store for Varian Medical (VAR) in Q3 Earnings?
by Zacks Equity Research
Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.
What's in Store for Align Technology (ALGN) in Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to deliver a strong second quarter on continued adoption of Invisalign system.
Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed
by Zacks Equity Research
Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.
Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.
What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.
Here's Why Investors Should Consider Cerner (CERN) Stock
by Zacks Equity Research
For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.
Falling Earnings Estimates Signal Weakness Ahead for Patterson Companies (PDCO)
by Zacks Equity Research
Patterson Companies (PDCO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
7 S&P 500-Beating Stocks to Buy Ahead of Q2 Earnings
by Aniruddha Ganguly
Here we pick seven stocks that have outperformed the S&P 500 and are likely to beat earnings estimates this reporting cycle.
Can Global Industrial Unit Drive Ecolab's (ECL) Q2 Earnings?
by Zacks Equity Research
Ecolab (ECL) likely to see impressive growth in second-quarter adjusted earnings per share.
Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.